Joined
·
1,181 Posts
It makes sense that the drug company would do European trials first. The FDA is so strict and the data they gather is extensive so it takes longer to market a drug. Thus drug companies go to Europe where they can perform drug studies without the restrictions. I saw Dr. John Daily's talk at the first IAD, and he discussed this subject. The epibatidine is attached to a toxic section of the molecule. They cleaved off the toxic part and found a possible drug for nicotine receptors. They can't make it in a lab, the molecule is too complex for chem labs to make, so they tried to make on as close as possible, to the original. I guess they succeeded. It is apparently 100 times more powerful than morphine at killing pain without the narcotic side effects (sedation, respiratory depression, etc). The target is for cancer patinets. :wink:
